BRPI0510567B8 - anticorpos isolados, vetores, células hospedeiras e usos dos ditos anticorpos - Google Patents
anticorpos isolados, vetores, células hospedeiras e usos dos ditos anticorposInfo
- Publication number
- BRPI0510567B8 BRPI0510567B8 BRPI0510567A BRPI0510567A BRPI0510567B8 BR PI0510567 B8 BRPI0510567 B8 BR PI0510567B8 BR PI0510567 A BRPI0510567 A BR PI0510567A BR PI0510567 A BRPI0510567 A BR PI0510567A BR PI0510567 B8 BRPI0510567 B8 BR PI0510567B8
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- vectors
- host cells
- cell
- nucleic acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56989204P | 2004-05-10 | 2004-05-10 | |
| US60/569,892 | 2004-05-10 | ||
| PCT/US2005/016357 WO2005110475A2 (en) | 2004-05-10 | 2005-05-10 | Antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0510567A BRPI0510567A (pt) | 2007-11-20 |
| BRPI0510567B1 BRPI0510567B1 (pt) | 2018-11-13 |
| BRPI0510567B8 true BRPI0510567B8 (pt) | 2021-05-25 |
Family
ID=35394680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0510567A BRPI0510567B8 (pt) | 2004-05-10 | 2005-05-10 | anticorpos isolados, vetores, células hospedeiras e usos dos ditos anticorpos |
Country Status (27)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20040116333A1 (en) * | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| BRPI0510561A (pt) * | 2004-05-11 | 2007-11-20 | Abgenomics Corp | epìtopos que induzem morte de célula t |
| WO2007067984A2 (en) * | 2005-12-09 | 2007-06-14 | Wyeth | Neutralizing antibodies against primate psgl-1 and uses therefor |
| CA2741798A1 (en) * | 2008-10-28 | 2010-05-06 | Shionogi & Co., Ltd. | Anti-muc1 antibody |
| TWI659474B (zh) * | 2008-10-31 | 2019-05-11 | Semiconductor Energy Laboratory Co., Ltd. | 半導體裝置及其製造方法 |
| GB0822011D0 (en) * | 2008-12-02 | 2009-01-07 | Queen Mary & Westfield College | Treatment |
| IN2015DN02826A (cg-RX-API-DMAC7.html) * | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| WO2012000094A1 (en) * | 2010-06-30 | 2012-01-05 | Mount Sinai Hospital | REAGENTS AND METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH HYDROXYLATED HIF 1-α |
| ES2387156B1 (es) * | 2010-12-01 | 2013-07-04 | Universidad Autónoma de Madrid | Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes |
| EP2718325A4 (en) * | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| WO2013057096A1 (en) | 2011-10-17 | 2013-04-25 | Westfaelische Wilhelms-Universitaet Muenster | Assessment of pml risk and methods based thereon |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| TWI595007B (zh) * | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗mcam抗體及相關使用方法 |
| US10988528B2 (en) * | 2015-08-13 | 2021-04-27 | New York University | Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
| WO2017120534A1 (en) * | 2016-01-08 | 2017-07-13 | Bioalliance C.V. | Tetravalent anti-psgl-1 antibodies and uses thereof |
| WO2017214941A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种提升SelP基因表达水平的慢病毒载体及其应用 |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| SG11202008593PA (en) | 2018-03-21 | 2020-10-29 | Five Prime Therapeutics Inc | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| AU2019301120A1 (en) | 2018-07-11 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
| KR20250024129A (ko) | 2018-07-20 | 2025-02-18 | 피에르 파브르 메디카먼트 | Vista의 수용체 |
| KR20220042055A (ko) * | 2019-06-04 | 2022-04-04 | 베르조 테라퓨틱스, 아이엔씨. | 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도 |
| JP7821733B2 (ja) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| JP2024540484A (ja) * | 2021-11-17 | 2024-10-31 | アルトゥルバイオ, インコーポレイテッド | 抗psgl-1抗体をjak阻害剤と組み合わせて使用してt細胞媒介性炎症性疾患またはがんを治療する方法 |
| TW202540180A (zh) * | 2023-11-17 | 2025-10-16 | 美商美國全心醫藥生技股份有限公司 | 抗psgl-1抗體及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5378464A (en) * | 1989-03-08 | 1995-01-03 | Board Of Regents Of The University Of Oklahoma | Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140 |
| US5464778A (en) * | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
| US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| US6309639B1 (en) * | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
| US6124267A (en) * | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
| US5972625A (en) * | 1991-05-06 | 1999-10-26 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
| AU673347B2 (en) | 1992-03-17 | 1996-11-07 | Novartis Ag | Genetically engineered antibodies |
| US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
| RU2151612C1 (ru) * | 1992-12-01 | 2000-06-27 | Протеин Дизайн Лэбс, Инк. | Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека |
| US6210671B1 (en) * | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| WO1994014836A1 (en) * | 1992-12-18 | 1994-07-07 | Centocor, Inc. | Peptide inhibitors of selectin binding |
| DE69415154T2 (de) * | 1993-01-25 | 1999-07-29 | Dana-Farber Cancer Institute, Inc., Boston, Mass. | Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen |
| CN1124928A (zh) * | 1993-05-04 | 1996-06-19 | 赛特尔公司 | P-选择蛋白抗体及其应用 |
| WO1995014787A1 (en) * | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
| DE69630307T2 (de) | 1995-08-03 | 2004-07-15 | The Board Of Regents Of The University Of Oklahoma, Norman | O-glycaninhibitoren von selectinvermittelten entzüngen |
| US6348581B1 (en) * | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
| JP3248570B2 (ja) * | 1997-10-09 | 2002-01-21 | 日本電気株式会社 | 半導体装置の製造方法 |
| WO1999043353A2 (en) * | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
| CN1342085A (zh) * | 1998-10-30 | 2002-03-27 | 遗传研究所有限公司 | 通过p-选择素配体(psgl)拮抗剂抑制细胞素t细胞的分化 |
| US6696620B2 (en) | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
| EP1289552B1 (en) * | 2000-05-19 | 2006-03-29 | The Center for Blood Research, INC. | Methods for treating hemostatic disorders by soluble p-selectin |
| CN1124928C (zh) * | 2000-07-11 | 2003-10-22 | 湛江包装材料企业有限公司 | 光降解双向拉伸聚丙烯薄膜的制造方法 |
| WO2002022820A1 (en) * | 2000-09-12 | 2002-03-21 | Genetics Institute, Llc | Inhibition of stenosis or restenosis by p-selectin antagonists |
| US20040002450A1 (en) * | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| PL366223A1 (en) | 2000-12-29 | 2005-01-24 | Bio-Technology General Corp. | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040001839A1 (en) * | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US6884619B2 (en) * | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
| US7744888B2 (en) * | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20040116333A1 (en) * | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| BRPI0510561A (pt) * | 2004-05-11 | 2007-11-20 | Abgenomics Corp | epìtopos que induzem morte de célula t |
| EP2718325A4 (en) | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
-
2005
- 2005-05-06 MY MYPI20052048A patent/MY148646A/en unknown
- 2005-05-06 UY UY28886A patent/UY28886A1/es not_active Application Discontinuation
- 2005-05-09 AR ARP050101855A patent/AR048781A1/es active IP Right Grant
- 2005-05-10 NZ NZ590690A patent/NZ590690A/xx not_active IP Right Cessation
- 2005-05-10 CA CA2907141A patent/CA2907141C/en not_active Expired - Fee Related
- 2005-05-10 SG SG10201606541UA patent/SG10201606541UA/en unknown
- 2005-05-10 BR BRPI0510567A patent/BRPI0510567B8/pt not_active IP Right Cessation
- 2005-05-10 JP JP2007513283A patent/JP5623690B2/ja not_active Expired - Lifetime
- 2005-05-10 TW TW094115123A patent/TWI402274B/zh not_active IP Right Cessation
- 2005-05-10 NZ NZ578647A patent/NZ578647A/en not_active IP Right Cessation
- 2005-05-10 CA CA2812040A patent/CA2812040C/en not_active Expired - Fee Related
- 2005-05-10 UA UAA200612974A patent/UA100356C2/ru unknown
- 2005-05-10 SG SG2013001474A patent/SG187443A1/en unknown
- 2005-05-10 EP EP11150345.4A patent/EP2377890B1/en not_active Expired - Lifetime
- 2005-05-10 CA CA2566305A patent/CA2566305C/en not_active Expired - Lifetime
- 2005-05-10 NZ NZ551626A patent/NZ551626A/en not_active IP Right Cessation
- 2005-05-10 ES ES05747985.9T patent/ES2448468T3/es not_active Expired - Lifetime
- 2005-05-10 ES ES11150339.7T patent/ES2598034T3/es not_active Expired - Lifetime
- 2005-05-10 TW TW101128378A patent/TWI448474B/zh not_active IP Right Cessation
- 2005-05-10 KR KR1020067024896A patent/KR101256400B1/ko not_active Expired - Fee Related
- 2005-05-10 DK DK05747985.9T patent/DK1765396T3/en active
- 2005-05-10 AU AU2005244072A patent/AU2005244072C1/en not_active Expired
- 2005-05-10 EP EP11150339.7A patent/EP2377889B1/en not_active Expired - Lifetime
- 2005-05-10 PT PT57479859T patent/PT1765396E/pt unknown
- 2005-05-10 EP EP05747985.9A patent/EP1765396B1/en not_active Expired - Lifetime
- 2005-05-10 PL PL05747985T patent/PL1765396T3/pl unknown
- 2005-05-10 CN CN200580023307.2A patent/CN1984680B/zh not_active Expired - Lifetime
- 2005-05-10 CN CN201410209919.1A patent/CN103980361B/zh not_active Expired - Fee Related
- 2005-05-10 ES ES11150345.4T patent/ES2602633T3/es not_active Expired - Lifetime
- 2005-05-10 WO PCT/US2005/016357 patent/WO2005110475A2/en not_active Ceased
- 2005-05-10 MX MXPA06012986A patent/MXPA06012986A/es active IP Right Grant
- 2005-05-10 US US11/125,837 patent/US7604800B2/en active Active
- 2005-05-10 RU RU2006143686/10A patent/RU2482131C2/ru not_active Application Discontinuation
-
2006
- 2006-10-24 IL IL178838A patent/IL178838A/en active IP Right Grant
- 2006-11-08 EG EGPCTNA2006001061A patent/EG26781A/en active
- 2006-12-01 NO NO20065542A patent/NO341844B1/no not_active IP Right Cessation
- 2006-12-08 EC EC2006007056A patent/ECSP067056A/es unknown
-
2009
- 2009-03-06 US US12/399,516 patent/US20090198044A1/en not_active Abandoned
- 2009-03-06 US US12/399,484 patent/US8287871B2/en not_active Expired - Lifetime
-
2010
- 2010-08-17 US US12/858,110 patent/US8361472B2/en not_active Expired - Fee Related
-
2011
- 2011-05-30 JP JP2011121078A patent/JP2011200247A/ja active Pending
-
2012
- 2012-09-14 US US13/616,849 patent/US8663641B2/en not_active Expired - Fee Related
- 2012-09-14 US US13/616,801 patent/US8828397B2/en not_active Expired - Fee Related
-
2013
- 2013-08-20 IL IL228032A patent/IL228032A0/en unknown
- 2013-08-20 IL IL228033A patent/IL228033A0/en unknown
-
2014
- 2014-01-10 JP JP2014003463A patent/JP2014094010A/ja active Pending
- 2014-07-31 JP JP2014156064A patent/JP2014223084A/ja not_active Withdrawn
- 2014-08-11 US US14/456,279 patent/US9631019B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 PH PH12015500247A patent/PH12015500247A1/en unknown
-
2017
- 2017-03-15 US US15/459,399 patent/US10030075B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0510567A (pt) | anticorpos | |
| CY1111629T1 (el) | Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| WO2003018771A3 (en) | A system for antibody expression and assembly | |
| NO20070985L (no) | IL-17 antagonistiske antistoffer. | |
| BRPI0314038B8 (pt) | anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica | |
| WO2006076594A3 (en) | Antibodies and fc fusion proteins with altered immunogenicity | |
| WO2007048022A3 (en) | Antibody-polypeptide fusion proteins and methods for producing and using same | |
| BRPI0606790A2 (pt) | anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. | |
| BRPI0519705A2 (pt) | composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo | |
| BR9608481A (pt) | Anticorpos quiméricos para administração de antìgenos a células selecionadas do sistema imunológico. | |
| DE60325611D1 (de) | Benzoat- und antranilatinduzierbare promotoren | |
| ATE504602T1 (de) | Für humane matriptase spezifische bindungsproteine | |
| AR076083A1 (es) | Anticuerpo monoclonal anti-rhesus d | |
| AR011740A1 (es) | Proteinas del virus que produce enrollamiento en las hojas de la vid del tipo 2, secuencias de codificacion y metodos | |
| DK0852623T3 (da) | Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler | |
| NO20052714D0 (no) | Fremgangsmater og materialer for behandling av inflammatoriske tilstander | |
| WO2008085551A3 (en) | Smallpox monoclonal antibody | |
| NO960748L (no) | Rekombinante Alternaria alternata allergener | |
| DK439086D0 (da) | Fremgangsmaader til anvendelse af cellelinier, der mangler humane klasseii histokompatibilitetsantigener | |
| Izumchenko et al. | 6 Yeast Hybrid Approaches | |
| Morrow Jr | Epitope tagging generates new products | |
| WO2000017372A3 (en) | Pineapple mealybug-associated wilt virus proteins and their uses | |
| AR109262A1 (es) | Anticuerpos contra tim3 y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ABGENOMICS COOEPERATIEF U.A. (NL) Free format text: TRANSFERIDO DE: ABGENOMICS CORPORATION |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: ABGENOMICS COOEPERATIEF U.A. (NL) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/11/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25G | Requested change of headquarter approved |
Owner name: ABGENOMICS COOEPERATIEF U.A. (NL) |
|
| B25A | Requested transfer of rights approved |
Owner name: ALTRUBIO INC. (US) |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
| B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2879 DE 10/03/2026 POR TER SIDO INDEVIDA. |